3M to sell drug delivery business to Altaris Capital for $650m

US industrial conglomerate 3M has signed a cash-cum-stock deal worth around $650 million to sell substantially all of its drug delivery business to an affiliate of Altaris Capital Partners for about $650 million, as per the latest pharma acquisition news. As per the terms of the deal, the total consideration includes cash, an interest-bearing security, More...

by pharmanewsdaily | Published 2 days ago
By pharmanewsdaily On Thursday, December 12th, 2019
0 Comments

Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) in patients who are treatment-naïve. The More...

By pharmanewsdaily On Thursday, December 12th, 2019
0 Comments

Leucadia launches Sodium Tetradecyl Sulfate injection for varicose veins

Leucadia Pharmaceuticals, the commercial sales unit of Custopharm, has launched the FDA-approved Sodium Tetradecyl Sulfate (STS) generic injection in the US. According to Leucadia Pharmaceuticals, the regulated More...

By pharmanewsdaily On Tuesday, December 10th, 2019
0 Comments

AbbVie, Scripps Research to collaborate on developing new therapeutics

US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for a variety of diseases, including in More...

By pharmanewsdaily On Monday, December 9th, 2019
0 Comments

GE Healthcare, ASLS form R&D partnership to advance 3D biofabrication

GE Healthcare Life Sciences has joined forces with Advanced Solutions Life Sciences (ASLS) for an R&D and distribution partnership with a goal to create new opportunities for regenerative tissue manufacturing More...

By pharmanewsdaily On Sunday, December 8th, 2019
0 Comments

Astellas Pharma to acquire US gene therapy company Audentes Therapeutics

Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition More...

By pharmanewsdaily On Sunday, December 8th, 2019
0 Comments

Janssen to acquire skin disease drug candidate bermekimab from XBiotech

Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational compound for certain skin More...

By pharmanewsdaily On Friday, December 6th, 2019
0 Comments

Precision oncology company Black Diamond Therapeutics raises $85m

Black Diamond Therapeutics, a precision oncology company based in Cambridge, has raised $85 million from a Series C financing round led by Boxer Capital of the Tavistock Group. Additional new investors in the Series More...

By pharmanewsdaily On Thursday, December 5th, 2019
0 Comments

AstraZeneca taps into Gatehouse Bio’s sRNAlytics AI platform for drug discovery

US biodata company Gatehouse Bio is joining forces with pharma giant AstraZeneca to accelerate the discovery of new drugs for respiratory and cardiovascular diseases using sRNAlytics, the former’s artificial More...

By pharmanewsdaily On Wednesday, December 4th, 2019
0 Comments

Soligenix all set to begin FLASH clinical trial for SGX301 in CTCL

US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 (synthetic hypericin) in cutaneous More...